Calcium-channel blockers for prophylaxis of radiocontrast-associated nephrotoxicity.
Because of both an absence of sufficient data and the concern for increased toxicity in certain patient populations, the use of CCBs to reduce radiocontrast-associated nephrotoxicity is not recommended. Additional prospective, randomized trials are needed.
Seyss
C
C
Department of Pharmacy Practice and Administration, College of Pharmacy, Rutgers, State University of New Jersey, Piscataway 08855, USA.
Foote
E F
EF
D058186:Acute Kidney Injury / Q000139:chemically induced / Q000517:prevention & control*; D000328:Adult; D000818:Animals; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003287:Contrast Media / Q000009:adverse effects*; D006801:Humans; D008875:Middle Aged; D009846:Oliguria / Q000139:chemically induced; D011446:Prospective Studies
D002121:Calcium Channel Blockers; D003287:Contrast Media